EFFICACY STUDY OF RECOMBINANT LEUKOCYTE A IFN IN HAIRY CELL LEUKEMIA

这项研究是一项古老但正在进行的研究， 毛细胞白血病患者的重组α干扰素。 五十六例患者被纳入本研究，其中 43继续治疗。 总体初始应答率为92 54例可评价反应的患者的百分比。 已有2 完全缓解，33例部分缓解，15例轻微缓解， 4例患者无应答。 2例患者无法评价 血液学反应。 一个只接受了一剂 在发现恶性神经胶质瘤之前， 第二名患者的血液学应答不可评价，因为 她接受了疼痛的骨受累治疗， 毛细胞 1例患者在300万单位剂量下无反应 每日剂量递增至每日600万单位，随后 有轻微的反应，目前仍在进行中。 7名患者 最初有反应的患者最终出现疾病进展。 六 这些患者接受了更高剂量的干扰素治疗， 回答道。 然而，这3例患者的反应是 有限且短暂。 43名有反应的患者继续 来回应 毒性很小，可以接受。 最常见的 副作用是轻微疲劳， 限制。

This study is an old but ongoing study evaluating the efficacy of recombinant alpha interferon in patients with hairy cell leukemia. Fifty-six patients have been admitted to this study and of these 43 continue on therapy. The overall initial response rate was 92 percent of 54 patients evaluable for response. There have been 2 complete responses, 33 partial responses, 15 minor responses, and 4 patients did not respond. Two patients are not evaluable for hematologic response. One received only a single dose of interferon prior to the discovery of a malignant glioma, and the second patient is not evaluable for hematologic response because she was treated for painful bony involvement proven to be due to hairy cells. One patient who did not respond at 3 million units daily was dose escalated to 6 million units daily and subsequently had a minor response which is ongoing. Seven patients who responded initially ultimately had disease progression. Six of these were treated with higher doses of interferon and 3 have responded. The response in these 3 patients however has been limited and transient. Forty-three responding patients continue to respond. Toxicity has been minimal and acceptable. The most common side effect has been minor fatigue which in no way has been limiting.